Nav: Home

Driver of non-small cell lung cancer, FGFR1, also in 23 percent of small cell lung cancer

April 19, 2015

Significant new treatments are available or in clinical trials for non-small cell lung cancer. The same explosion in treatment options is not true for the disease's cousin, small cell lung cancer, the less common and more aggressive form of the disease. Results presented by the University of Colorado Cancer Center at the American Association for Cancer Research Annual Meeting 2015 show the presence of a known driver of non-small cell lung cancer in small cell lung cancer, implying that promising treatments in development for the first may be applicable to the second form of the disease as well.

"There is an unmet need in small cell lung cancer. There have been no significant new therapies developed in 20 years," says Fred R. Hirsch, MD, PhD, associate director for international programs at the University of Colorado Cancer Center and CEO of the International Association for the Study of Lung Cancer.

One promising new strategy in the treatment of non-small cell lung cancer is the inhibition fibroblast growth factor receptor (FGFR), which helps to signal uncontrolled, cancerous growth in about 21 percent of non-small cell lung cancers. Results presented by Hirsch and colleagues at AACR 2015 show positivity for FGFR1 amplification, mRNA and/or protein expression in 17 of 75 patient samples (22.7 percent) of small cell lung cancer tumors.

"The presence of FGFR1 as a driver mutation in small cell lung cancer implies that we could repurpose drugs that target this amplification in non-small cell lung cancer for the small cell form of the disease," Hirsch says.

Small cell lung cancer accounts for 10 to 15 percent of all lung cancers, with 5-year survival rates less than half that of non-small cell lung cancer. Because small cell lung cancer shows symptoms much later than non-small cell lung cancer, it is usually diagnosed much later in the course of the disease, commonly after it has metastasized to other parts of the body, and thus many patients die within weeks or months of diagnosis.

The study identifies a subset of patients with small cell lung cancer with potentially over activated FGFR1 pathways as evidenced by FGFR1 gene amplification, increased FGFR1 mRNA levels, and high protein expression.

"This clearly demonstrates that FGFR1 is important in a subgroup of small cell lung cancers. I would say this will lead to a clinical trial of drugs targeting FGFR in small cell lung cancer," Hirsch says. "The progress of existing drugs targeting FGFR1 means that we could be much closer to offering treatment options to people with small cell lung cancer than if we had been forced to start with a new compound."

University of Colorado Anschutz Medical Campus

Related Lung Cancer Articles:

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.
Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.
Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.
Better equipped in the fight against lung cancer
Lung cancer is the third most common type of cancer in Germany and the disease affects both men and women.
New liquid biopsy-based cancer model reveals data on deadly lung cancer
Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes.
Cancer drug leads to 'drastic decrease' in HIV infection in lung cancer patient
Doctors in France have found the first evidence that a cancer drug may be able to eradicate HIV-infected cells in humans.
Air pollution is associated with cancer mortality beyond lung cancer
A large scale epidemiological study associates some air pollutants with kidney, bladder and colorectal cancer death.
More Lung Cancer News and Lung Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Making Amends
What makes a true apology? What does it mean to make amends for past mistakes? This hour, TED speakers explore how repairing the wrongs of the past is the first step toward healing for the future. Guests include historian and preservationist Brent Leggs, law professor Martha Minow, librarian Dawn Wacek, and playwright V (formerly Eve Ensler).
Now Playing: Science for the People

#566 Is Your Gut Leaking?
This week we're busting the human gut wide open with Dr. Alessio Fasano from the Center for Celiac Research and Treatment at Massachusetts General Hospital. Join host Anika Hazra for our discussion separating fact from fiction on the controversial topic of leaky gut syndrome. We cover everything from what causes a leaky gut to interpreting the results of a gut microbiome test! Related links: Center for Celiac Research and Treatment website and their YouTube channel
Now Playing: Radiolab

The Third. A TED Talk.
Jad gives a TED talk about his life as a journalist and how Radiolab has evolved over the years. Here's how TED described it:How do you end a story? Host of Radiolab Jad Abumrad tells how his search for an answer led him home to the mountains of Tennessee, where he met an unexpected teacher: Dolly Parton.Jad Nicholas Abumrad is a Lebanese-American radio host, composer and producer. He is the founder of the syndicated public radio program Radiolab, which is broadcast on over 600 radio stations nationwide and is downloaded more than 120 million times a year as a podcast. He also created More Perfect, a podcast that tells the stories behind the Supreme Court's most famous decisions. And most recently, Dolly Parton's America, a nine-episode podcast exploring the life and times of the iconic country music star. Abumrad has received three Peabody Awards and was named a MacArthur Fellow in 2011.